Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening

Cellular Oncology

Volumn 34, Issue 6, 2011, Pages 511-521

  Pérez Torras, Sandra ^a,d   Vidal Pla, Anna ^a   Miquel, Rosa ^b   Almendro, Vanessa ^b   Fernández Cruz, Laureano ^b   Navarro, Salvador ^b,c,d   Maurel, Joan ^b,c,d   Carbó, Neus ^a   Gascón, Pere ^b,c,e   Mazo, Adela ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e Red Tematica de Investigacion Cooperativa en Cancer   (Spain)

Author keywords

Biomarker; Drug screening; Orthotopic; Pancreatic cancer; Xenograft

Indexed keywords

K RAS PROTEIN; PROTEIN P53; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KINETICS; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TUMOR XENOGRAFT; PANCREAS ADENOCARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; GENETICS; IN VITRO STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861497889     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-011-0049-1     Document Type: Article

References (38)

1. H.L. Kindler, Pancreatic cancer: an update. Curr. Oncol. Rep. 9, 170-176 (2007) (Pubitemid 46736349)
2. J.D. Berlin, P. Catalano, J.P. Thomas, J.W. Kugler, D.G. Haller, A. B. Benson 3rd, Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 20, 3270-3275 (2002) (Pubitemid 34831525)
3. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M.J. Thun, Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008)
4. J.E. Talmadge, R.K. Singh, I.J. Fidler, A. Raz, Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 170, 793-804 (2007) (Pubitemid 47339349)
5. B. Rubio-Viqueira, A. Jimeno, G. Cusatis, X. Zhang, C. Iacobuzio-Donahue, C. Karikari, C. Shi, K. Danenberg, P.V. Danenberg, H. Kuramochi, K. Tanaka, S. Singh, H. Salimi-Moosavi, N. Bouraoud, M.L. Amador, S. Altiok, P. Kulesza, C. Yeo, W. Messersmith, J. Eshleman, R.H. Hruban, A. Maitra, M. Hidalgo, An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4652-4661 (2006) (Pubitemid 44297818)
6. B. Rubio-Viqueira, M. Hidalgo, Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin. Pharmacol. Ther. 85, 217-221 (2009)
7. X. Fu, F. Guadagni, R.M. Hoffman, A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl Acad. Sci. U.S. A. 89, 5645-5649 (1992)
8. G. Capella, L. Farre, A. Villanueva, G. Reyes, C. Garcia, G. Tarafa, F. Lluis, Orthotopic models of human pancreatic cancer. Ann. NY Acad. Sci. 880, 103-109 (1999) (Pubitemid 29349118)
9. K. Garber, From human to mouse and back: 'tumorgraft' models surge in popularity. J. Natl. Cancer Inst. 101, 6-8 (2009)
10. C. Sorio, A. Bonora, S. Orlandini, P.S.Moore, P. Capelli, P. Cristofori, G. Dal Negro, P.Marchiori, G. Gaviraghi,M. Falconi, P. Pederzoli, G. Zamboni, A. Scarpa, Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch. 438, 154-158 (2001) (Pubitemid 32186583)
11. M.P. Kim, D.B. Evans, H. Wang, J.L. Abbruzzese, J.B. Fleming, G.E. Gallick, Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc. 4, 1670-1680 (2009)
12. R.M. Hoffman, Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New. Drugs. 17, 343-359 (1999) (Pubitemid 30135902)
13. P.A. Philip, M. Mooney, D. Jaffe, G. Eckhardt, M. Moore, N. Meropol, L. Emens, E. O'Reilly, M. Korc, L. Ellis, J. Benedetti, M. Rothenberg, C. Willett, M. Tempero, A. Lowy, J. Abbruzzese, D. Simeone, S. Hingorani, J. Berlin, J. Tepper, Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J. Clin. Oncol. 27, 5660-5669 (2009)
14. J. Kononen, L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, S. Leighton, J. Torhorst, M.J. Mihatsch, G. Sauter, O. P. Kallioniemi, Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844-847 (1998) (Pubitemid 28331029)
15. S. Kumar, V.M. Weaver, Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 28, 113-127 (2009)
16. G.C. Chu, A.C. Kimmelman, A.F. Hezel, R.A. DePinho, Stromal biology of pancreatic cancer. J. Cell. Biochem. 101, 887-907 (2007) (Pubitemid 47040870)
17. A.L. Kung, Practices and pitfalls of mouse cancer models in drug discovery. Adv. Cancer Res. 96, 191-212 (2007)
18. H.G. Hotz, H.A. Reber, B. Hotz, T. Yu, T. Foitzik, H.J. Buhr, G. Cortina, O.J. Hines, An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas. 26, e89-e98 (2003)
19. S. Marchan, S. Perez-Torras, A. Vidal, J. Adan, F. Mitjans, N. Carbo, A. Mazo, Dual effects of beta3 integrin subunit expression on human pancreatic cancer models. Anal. Cell Pathol/Cellular Oncology 33, 191-205 (2010)
20. M. Andrianifahanana, N. Moniaux, B.M. Schmied, J. Ringel, H. Friess, M.A. Hollingsworth, M.W. Buchler, J.P. Aubert, S.K. Batra, Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin. Cancer Res. 7, 4033-4040 (2001) (Pubitemid 34044624)
21. K. Nagata, M. Horinouchi, M. Saitou, M. Higashi, M. Nomoto, M. Goto, S. Yonezawa, Mucin expression profile in pancreatic cancer and the precursor lesions. J. Hepatobiliary Pancreat Surg. 14, 243-254 (2007) (Pubitemid 46863913)
22. A.P. Singh, P. Chaturvedi, S.K. Batra, Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res. 67, 433-436 (2007) (Pubitemid 46192176)
23. A. Westgaard, A.R. Schjolberg, M. Cvancarova, T.J. Eide, O.P. Clausen, I.P. Gladhaug, Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology. 54, 337-347 (2009)
24. S. Meer, M. Altini, CK7+/CK20-immunoexpression profile is typical of salivary gland neoplasia. Histopathology. 51, 26-32 (2007) (Pubitemid 46976374)
25. F.H. Schmitz-Winnenthal, C. Volk, B. Helmke, S. Berger, U. Hinz, M. Koch, J. Weitz, J. Kleeff, H. Friess, M. Zoller, M.W. Buchler, K. Z'Graggen, Expression of cytokeratin-20 in pancreatic cancer: an indicator of poor outcome after R0 resection. Surgery. 139, 104-108 (2006) (Pubitemid 41814438)
26. M.C. Bibby, Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur. J. Cancer 40, 852-857 (2004) (Pubitemid 38519764)
27. H.H. Fiebig, A. Maier, A.M. Burger, Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 40, 802-820 (2004) (Pubitemid 38519759)
28. E. Karna, A. Surazynski, K. Orlowski, J. Laszkiewicz, Z. Puchalski, P. Nawrat, J. Palka, Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int. J. Exp. Pathol. 83, 239-245 (2002) (Pubitemid 36321742)
29. U. Bergmann, H. Funatomi, M. Yokoyama, H.G. Beger, M. Korc, Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 55, 2007-2011 (1995)
30. S. Ueda, K. Hatsuse, H. Tsuda, S. Ogata, N. Kawarabayashi, T. Takigawa, T. Einama, D. Morita, K. Fukatsu, Y. Sugiura, O. Matsubara, H. Mochizuki, Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod. Pathol. 19, 788-796 (2006) (Pubitemid 43780448)
31. H. Werner, I. Bruchim, The insulin-like growth factor-I receptor as an oncogene. Arch. Physiol. Biochem. 115, 58-71 (2009)
32. C. Horndler, R. Gallego, X. Garcia-Albeniz, V. Alonso-Espinaco, V. Alonso, P. Escudero, M. Jimeno, J. Ortego, J. Codony-Servat, C. Fernandez-Martos, A. Calatrava, M. Marin-Aguilera, J. Munoz, S. Castellvi-Bel, A. Castells, M. Rubini, P. Gascon, J. Maurel, Coexpression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol. Ther. 11, 177-83 (2011)
33. M. Guix, M. Granja Nde, I. Meszoely, T.B. Adkins, B.M. Wieman, K.E. Frierson, V. Sanchez, M.E. Sanders, A.M. Grau, I.A. Mayer, G. Pestano, Y. Shyr, S.Muthuswamy, B. Calvo, H. Krontiras, I.E. Krop, M.C. Kelley, C.L. Arteaga, Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptorpositive breast cancers. J. Clin. Oncol. 26, 897-906 (2008) (Pubitemid 351398082)
34. S. Miyamoto, K. Yano, S. Sugimoto, G. Ishii, T. Hasebe, Y. Endoh, K. Kodama, M. Goya, T. Chiba, A. Ochiai, Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 64, 665-671 (2004) (Pubitemid 38120908)
35. A.C. Williams, H. Smartt, A.M. H-Zadeh, M. Macfarlane, C. Paraskeva, T.J. Collard, Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ. 14, 137-145 (2007) (Pubitemid 44911901)
36. F. Ozawa, H. Friess, J. Kleeff, Z.W. Xu, A. Zimmermann, M.S. Sheikh, M.W. Buchler, Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 163, 71-81 (2001) (Pubitemid 32121832)
37. J. Li, M.W. Saif, Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP 10, 361-365 (2009)
38. M.T. Mueller, P.C. Hermann, J. Witthauer, B. Rubio-Viqueira, S.F. Leicht, S. Huber, J.W. Ellwart, M. Mustafa, P. Bartenstein, J.G. D'Haese, M.H. Schoenberg, F. Berger, K.W. Jauch, M. Hidalgo, C. Heeschen, Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137, 1102-1113 (2009)